Join us at the 2025 Cutting Edge of Transplantation (CEoT) – Transforming Tomorrow: Leading the Way in Organ Transplantation Modernization – from February 27 to March 1 in Scottsdale, AZ. Register today to be part of the future of transplantation.

The Fellow of the American Society of Transplantation (FAST) designation application is now open to all members who meet the eligibility criteria. Don't miss out on joining this prestigious program and be recognized for your contributions to transplantation!

For a limited time, the AST is offering an exclusive membership discount to transplant trainees. We're on a mission to help trainees boost their careers using the AST's benefits.

Through March 31, 2025, trainees can join the AST for just $60. To join with this promotion, you must qualify as a transplant trainee and be approved for membership. To receive the discount, use code TRAINEE2025.

Great news! Medical students can now join AST through our expanded Trainee Membership, which also welcomes those who have completed their training but haven’t yet qualified for Full or International membership. Additionally, our new Affiliate Membership category provides a home for professionals in the healthcare industry with a business interest in transplant. We’re excited to grow our community and encourage you to spread the word!

Many members have inquired about the AST's role, engagement, and impact in addressing the ongoing and quite-fluid HHS-HRSA OPTN modernization process. Rest assured that your Society has been, and continues to be, at the table with HHS, HRSA, Congress, patients, and the stakeholder community from day one. The AST has worked diligently from the very beginning to strategically position the Society to keep the door open for engaging our government partners and all stakeholders throughout the modernization initiative.

The AST is forming a task force on Living Donation Incentives to explore ethical, social, and financial considerations around incentivizing living donation in the United States. Learn more about this opportunity today.

The AST is pleased to announce its call for nominations for the 2025 Achievement Awards.

Each year, the AST honors its members’ accomplishments and contributions to the field of transplantation through the Achievement Awards. Members are recognized at different levels of their careers with Basic Science Awards, Clinical Science Awards, and Distinguished Career Awards. Nominate a colleague today!

On behalf of the PSECOP and WHCOP, we would like to invite you to participate in a quick survey, titled Gender Identity Knowledge Among Transplant Professionals.

The aim of the survey is to understand providers’ knowledge and experience providing care to LGBTQ+ identifying patients. Providers include all those who participate in the transplant process, including but not limited to advanced care providers (APPs), coordinators, ethicists, nurses, pharmacists, psychologists, physicians, and surgeons.

The survey has been approved by the AST Education Committee. It will take 5-10 minutes to complete.

Thank you in advance for your time and participation.

The AST developed a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. Our goal is to establish a platform for our membership to share their invaluable ideas and perspectives and actively engage with the Public Policy Committee and AST leadership. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.

Normothermic machine perfusion (NMP) has been shown to reduce peritransplant complications. Despite increasing NMP use in liver transplant (LT), there is a scarcity of real-world clinical experience data.

We aimed to assess contemporary transplant outcomes among kidney recipients with amyloidosis, as the treatment and prognosis of amyloidosis have shown improvement over time.

Recent advances in membranous nephropathy treatment have focused on B cell depletion, which is incompletely effective, potentially due to persistent autoantibody-producing plasma cells or alternative pathways of injury. T cell costimulatory blockade (cytotoxic-T-lymphocyte-associated antigen 4 (CTLA4)-Ig) to prevent T cell-dependent B cell activation and short-course proteasome inhibition (bortezomib) to deplete plasma cells may represent a complementary form of treatment.